Alnylam Pharmaceuticals (ALNY) vs Royalty Pharma (RPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Royalty Pharma (RPRX) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 57.5% versus a loss of 49.1%. Over five years, RPRX leads with a +48.3% price change compared with +11.6% for ALNY. Royalty Pharma is the larger company by market cap ($32.90 billion vs $31.13 billion), about 1.1 times the size, while Alnylam Pharmaceuticals is growing revenue faster (+65.2% vs +5.1%).
On valuation, Royalty Pharma trades at a lower forward P/E (9.9x vs 18.7x for Alnylam Pharmaceuticals). Royalty Pharma pays a dividend yielding 1.60%, while Alnylam Pharmaceuticals does not currently pay one. Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | RPRX |
|---|---|---|
| Share price | $232.68 | $56.93 |
| Market cap | $31.13B | $32.90B |
| 1-day change | +3.63% | +1.28% |
| YTD return | -41.49% | +47.33% |
| 1-year return | -49.08% | +57.53% |
| 5-year return | +11.57% | +48.29% |
| P/E ratio (TTM) | 37.83 | 29.96 |
| Forward P/E | 18.73 | 9.93 |
| EPS (TTM) | $6.15 | $1.90 |
| Dividend yield | 0.00% | 1.60% |
| Annual dividend | $0.00 | $0.91 |
| Revenue (latest FY) | $3.71B | $2.38B |
| Revenue growth (YoY) | +65.19% | +5.06% |
| Net income (latest FY) | $313.75M | $770.95M |
| Gross margin | 81.77% | — |
| Operating margin | 13.51% | 65.58% |
| Net margin | 8.45% | 32.42% |
| 52-week high | $495.55 | $64.38 |
| 52-week low | $197.81 | $35.23 |
| Distance from 52-week high | -53.05% | -11.57% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +59.50% | +14.84% |
| Average volume | 1.77M | 2.93M |
| Shares outstanding | 133.81M | 445.28M |
| Employees | 2,500 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RPRX has outperformed ALNY by 106.6 percentage points over the past year.
- Alnylam Pharmaceuticals trades at a higher earnings multiple (37.8x vs 30.0x trailing P/E).
- Royalty Pharma offers a meaningfully higher dividend yield (1.60% vs 0.00%).
- Royalty Pharma is more profitable, keeping 32.4 cents of every revenue dollar as net income versus 8.4 cents for Alnylam Pharmaceuticals.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +5.06%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
ALNY vs RPRX FAQ
Which is bigger, Alnylam Pharmaceuticals or Royalty Pharma?
Royalty Pharma (RPRX) is larger, with a market capitalization of $32.90B compared with $31.13B for Alnylam Pharmaceuticals (ALNY).
Which stock has performed better over the past year, ALNY or RPRX?
RPRX returned +57.53% over the past 12 months, compared with -49.08% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or RPRX?
RPRX has the lower trailing P/E at 30.0, versus 37.8 for ALNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Alnylam Pharmaceuticals or Royalty Pharma?
Royalty Pharma pays a dividend yielding 1.60%, while Alnylam Pharmaceuticals does not currently pay a regular dividend.
Are Alnylam Pharmaceuticals and Royalty Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.